Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of IBD
3.2.1.2 Technological advancements
3.2.1.3 Favorable reimbursement policies
3.2.1.4 Growing awareness and early diagnosis of IBD symptoms
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory scenario
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Reimbursement scenario
3.5 Regulatory landscape
3.6 Epidemiological scenario
3.7 Future market trends
3.8 Pipeline analysis
3.9 Pricing analysis, 2023
3.10 Brand analysis
3.11 Porter's analysis
3.12 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Crohn's disease
5.3 Ulcerative colitis
Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 TNF inhibitors
6.3 Aminosalicylates
6.4 Corticosteroids
6.5 IL inhibitors
6.6 JAK inhibitors
6.7 Anti-integrin
6.8 Other drug classes
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Injectable
7.3 Oral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacy
8.3 Retail pharmacy
8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc
10.2 Amgen Inc.
10.3 Biogen
10.4 CELLTRION INC
10.5 Dr Falk Pharma UK Ltd
10.6 Ferring B.V.
10.7 Ferring B.V.
10.8 Johnson & Johnson
10.9 Lilly
10.10 Novartis AG
10.11 Pfizer Inc
10.12 Takeda Pharmaceutical Company Limited
10.13 Tillotts Pharma AG
10.14 UCB Group
